Tarsus Pharmaceuticals, Inc. Common Stock
TARS
$56.25
-6.01%
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class therapeutics for ophthalmic conditions, with its lead product XDEMVY targeting Demodex blepharitis. The company occupies a unique niche as a pioneer in treating Demodex-related eye disease, leveraging its expertise in ocular surface disorders to build a differentiated pipeline. Investor attention is centered on XDEMVY's commercial ramp, as evidenced by strong revenue growth from $78.3 million in Q1 2025 to $162.1 million in Q1 2026, alongside ongoing losses that highlight the tension between top-line momentum and profitability timelines. The stock's recent volatility reflects debates around pipeline progress, competitive positioning, and the path to sustained profitability.…
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
$56.25
Investment Opinion: Should I buy TARS Today?
Rating: Buy. The thesis is that Tarsus is a commercial-stage biotech with a rapidly scaling product, improving profitability, and significant upside to analyst targets, despite near-term technical weakness. The consensus rating is Strong Buy with an average target of $94.56, implying 64.4% upside.
Supporting evidence: Revenue grew 106.9% YoY to $162.1M in Q1 2026, with gross margin of 94.2% providing strong operating leverage. Net loss narrowed from -$25.1M to -$7.0M, and net margin improved from -32.1% to -4.3%. The forward PE of 34.6x implies the market expects profitability within the next year, while the PS of 7.58x is in line with the biotech industry average. Free cash flow remains negative at -$30.5M, but the healthy balance sheet (current ratio 3.85, debt-to-equity 0.27) provides a cushion.
Risks & Conditions: The biggest risks are a slowdown in XDEMVY growth, failure to achieve profitability as expected, or adverse regulatory/competitive developments. This Buy rating would be downgraded to Hold if revenue growth decelerates below 50% YoY or if the company reports a wider-than-expected loss. It would be upgraded to Strong Buy if the company achieves positive net income in the next two quarters. Overall, TARS appears fairly valued relative to its growth rate (PEG 1.07x) but undervalued relative to analyst targets, offering a favorable risk/reward for investors with a 12-month horizon.
Sign up to view all
TARS 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Tarsus demonstrates exceptional revenue growth and a clear path to profitability, supported by high gross margins and improving operating leverage. The stock's recent decline appears overdone relative to fundamentals, creating a potential buying opportunity. However, the lack of profitability and negative free cash flow warrant caution, and the stock's low beta suggests company-specific risks dominate. Key developments to watch are the next earnings report for signs of continued margin improvement and any pipeline catalysts. An upgrade to high confidence would require positive net income, while a downgrade would follow a significant growth deceleration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tarsus Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $94.56 and implied upside of +68.1% versus the current price.
Average Target
$94.56
0 analysts
Implied Upside
+68.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$88 - $104
Analyst target range
The stock is covered by 9 analysts, with a consensus recommendation of Strong Buy (mean rating 1.11 on a 1-5 scale). The average target price is $94.56, implying a 64.4% upside from the current price of $57.50. The distribution shows no Hold or Sell ratings, reflecting unanimous bullish sentiment among covering analysts. This strong consensus is supported by recent institutional actions, with firms like HC Wainwright, Oppenheimer, and Guggenheim reiterating Buy ratings in 2026. The target range spans from a low of $88.00 to a high of $104.00, representing a spread of $16.00 or 18.2% of the average target. The high target of $104.00 implies an 80.9% upside and likely assumes continued revenue acceleration, margin expansion, and potential pipeline catalysts. The low target of $88.00 still implies a 53.0% upside, suggesting even the most conservative analyst sees significant value. The relatively tight spread indicates high conviction among analysts, though the small coverage universe (9 analysts) means the stock may be less efficiently priced than larger-cap biotechs. The unanimous Buy ratings and strong upside potential underscore the market's optimism about XDEMVY's commercial trajectory and the path to profitability.
Bulls vs Bears: TARS Investment Factors
Tarsus Pharmaceuticals presents a compelling growth story with XDEMVY's rapid revenue ramp, improving margins, and a clear path to profitability. The bull case is supported by 106.9% YoY revenue growth, narrowing losses, and unanimous analyst bullishness with 64% upside to the average target. However, the bear case highlights ongoing cash burn, high SG&A costs, and a stock in a significant downtrend that has underperformed the market by 39.5% YTD on a relative basis. The single most important tension is whether the company can achieve sustained profitability as expected — if margins continue to improve and the company reaches breakeven in the next 2-3 quarters, the current valuation (PS 7.58x) could prove cheap; if profitability is delayed, the stock could face further de-rating. Currently, the bull case has stronger evidence given the revenue trajectory and analyst consensus, but the technical weakness warrants caution.
Bullish
- Strong Revenue Growth Trajectory: Revenue grew 106.9% YoY from $78.3M in Q1 2025 to $162.1M in Q1 2026, with sequential growth from $151.7M in Q4 2025. This accelerating adoption of XDEMVY demonstrates strong commercial execution and market penetration.
- Path to Profitability Improving: Net loss narrowed from -$25.1M in Q1 2025 to -$7.0M in Q1 2026, with net margin improving from -32.1% to -4.3%. Operating margin also improved from -33.5% to -3.8%, indicating the company is approaching breakeven.
- High Gross Margin Supports Scalability: Gross margin reached 94.2% in Q1 2026, typical for biotech products with low COGS. This high margin provides a strong foundation for operating leverage as revenue scales, allowing incremental revenue to drop through to profits.
- Strong Analyst Conviction: All 9 analysts rate the stock a Strong Buy with a mean rating of 1.11/5. The average target price of $94.56 implies 64.4% upside from $57.50, with the low target of $88 still offering 53% upside.
Bearish
- Still Unprofitable with Negative FCF: Despite revenue growth, the company posted a net loss of -$7.0M and negative free cash flow of -$30.5M in Q1 2026. The negative FCF yield of -274.8x highlights ongoing cash burn to support growth.
- High SG&A Costs Weigh on Margins: SG&A expenses were $136.4M in Q1 2026, representing 84% of revenue. This high cost structure is typical for a commercial launch but leaves little room for error if revenue growth decelerates.
- Stock in Downtrend, Underperforming Market: The stock is down 28.8% YTD and 15.1% over 3 months, significantly underperforming the S&P 500 (+6.3% over 3 months). The 1-month relative strength of -7.6% indicates persistent selling pressure.
- Valuation Dependent on Profitability Inflection: The trailing PE of -51.5x and forward PE of 34.6x imply the market expects a swing to profitability within a year. If profitability is delayed, the stock could re-rate lower, as the current PS of 7.58x offers no margin of safety for earnings disappointments.
TARS Technical Analysis
The stock is in a pronounced downtrend over the past year, with a 1-year price change of +41.7% masking significant recent weakness. The current price of $57.50 sits at 67.5% of its 52-week range ($38.51 low to $85.25 high), indicating it has pulled back sharply from the highs and is now closer to the lower end of the range. This positioning suggests the stock is oversold relative to its 52-week peak but still above the low, reflecting a potential value opportunity if fundamentals support a recovery, though the downtrend momentum warrants caution. Short-term momentum is decisively negative, with a 1-month price change of -7.0% and a 3-month change of -15.1%, both underperforming the S&P 500's respective gains of +0.6% and +6.3%. This divergence from the longer-term 1-year gain of +41.7% signals a sharp reversal from prior highs, suggesting the stock is experiencing a significant pullback or trend change rather than a mere consolidation. The relative strength metrics confirm broad underperformance, with 1-month relative strength of -7.6% and 3-month relative strength of -21.4%. Key support lies at the 52-week low of $38.51, a breakdown below which would signal a bearish continuation and potential new lows. Resistance is at the 52-week high of $85.25; a breakout above this level would indicate a resumption of the prior uptrend. The stock's beta of 0.499 implies it is significantly less volatile than the market, meaning its recent declines are not amplified by market swings but rather driven by company-specific factors. This low beta suggests that position sizing can be more aggressive relative to high-beta names, but the current downtrend still demands disciplined risk management.
Beta
0.50
0.50x market volatility
Max Drawdown
-32.0%
Largest decline past year
52-Week Range
$39-$85
Price range past year
Annual Return
+30.1%
Cumulative gain past year
| Period | TARS Return | S&P 500 |
|---|---|---|
| 1m | -10.9% | -0.6% |
| 3m | -12.8% | +5.4% |
| 6m | -21.0% | +8.3% |
| 1y | +30.1% | +18.3% |
| ytd | -30.4% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TARS Fundamental Analysis
Revenue is growing rapidly, with Q1 2026 revenue of $162.1 million representing a 106.9% year-over-year increase from $78.3 million in Q1 2025. The sequential trend is also strong, with revenue rising from $151.7 million in Q4 2025, indicating accelerating commercial adoption of XDEMVY. Product revenue of $145.4 million in Q1 2026 dominates, while license and collaboration revenue contributed $16.7 million, showing the core business is driven by product sales. This growth trajectory supports the investment case for a commercial-stage biotech with a successful product launch, though investors will watch for sustained momentum. The company remains unprofitable, with a net loss of -$7.0 million in Q1 2026, though this loss has narrowed dramatically from -$25.1 million in Q1 2025. Gross margin is exceptionally high at 94.2% in Q1 2026, typical for biotech products with low cost of goods sold, but operating margin remains negative at -3.8%, reflecting heavy SG&A spending of $136.4 million. The improving net margin from -32.1% in Q1 2025 to -4.3% in Q1 2026 shows a clear trajectory toward profitability, which is critical for the investment thesis. The balance sheet is healthy with a current ratio of 3.85 and low debt-to-equity of 0.27, indicating ample liquidity and minimal leverage. Free cash flow was -$30.5 million in Q1 2026, though this improved from -$21.2 million in Q1 2025, and the company had $102.2 million in cash at the end of Q1 2026. ROE of -19.3% reflects ongoing losses, but the negative FCF yield of -274.8x (P/CF) highlights that the company is still burning cash to fund growth, though the low debt levels provide a cushion.
Quarterly Revenue
$162054000.0B
2026-03
Revenue YoY Growth
+106.9%
YoY Comparison
Gross Margin
94.2%
Latest Quarter
Free Cash Flow
$-31539000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TARS Overvalued?
Since net income is negative (TTM net income of -$6.97 million), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 7.58x, while no forward PS is available, but the PEG ratio of 1.07x suggests the market expects strong earnings growth ahead. The gap between the negative trailing PE of -51.5x and the forward PE of 34.6x implies the market anticipates a swing to profitability within the next year, which is a critical assumption for the current valuation. Compared to the biotechnology industry average PS ratio (typically 5-10x for commercial-stage biotechs), TARS trades at a PS of 7.58x, roughly in line with the sector median. This suggests the market is pricing in the strong revenue growth but not assigning a significant premium, likely due to the lack of profitability and pipeline risk. The EV/Sales multiple of 4.06x further confirms a moderate valuation relative to revenue. Historically, TARS's PS ratio has ranged from extreme levels (over 1,000x in early 2021) to current levels around 7.6x, which is near the lower end of its historical band over the past two years. This indicates the stock is trading at a discount to its own history, potentially reflecting the market's skepticism about sustained growth or profitability timelines. The current PS is well below the 23.1x level seen in Q4 2025, suggesting a significant de-rating that could present a value opportunity if the company delivers on earnings expectations.
PE
-51.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-62.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the company's ongoing unprofitability and negative free cash flow. Despite narrowing losses, TARS burned $30.5M in FCF in Q1 2026, and the negative FCF yield of -274.8x indicates the stock is priced for a profitability inflection that has not yet materialized. SG&A expenses of $136.4M (84% of revenue) are high for a company with only one product, creating operating leverage risk if revenue growth slows. The debt-to-equity of 0.27 is low, but the negative ROE of -19.3% reflects persistent losses that erode shareholder equity. Revenue concentration in XDEMVY (90% of total revenue) means any disruption to this product would severely impact financials.
Market & Competitive Risks: The stock's beta of 0.499 suggests low market correlation, meaning its recent 28.8% YTD decline is driven by company-specific factors rather than macro. The PS ratio of 7.58x is in line with biotech industry averages but has compressed from 23.1x in Q4 2025, indicating a significant de-rating that could continue if growth disappoints. Competitive risk is moderate — while XDEMVY is first-in-class for Demodex blepharitis, future entrants could erode market share. The unanimous Strong Buy rating from 9 analysts provides a floor, but the small coverage universe means the stock may be less efficiently priced. No recent news highlights emerging threats, but the stock's 1-month relative strength of -7.6% suggests negative sentiment.
Worst-Case Scenario: The most damaging scenario would be a significant slowdown in XDEMVY revenue growth (e.g., below 50% YoY) combined with continued cash burn, leading to analyst downgrades and a loss of investor confidence. In this scenario, the stock could fall to its 52-week low of $38.51, representing a 33% decline from the current price of $57.50. The historical max drawdown of -32% suggests this level of decline is plausible. If the company also announces a dilutive equity offering to fund operations, the downside could be even greater, potentially testing the $35 level.
FAQ
The key risks are: 1) Financial risk — the company is unprofitable with negative free cash flow (-$30.5M in Q1 2026), and any delay in achieving profitability could lead to stock de-rating. 2) Single-product concentration — XDEMVY accounts for 90% of revenue, making the company vulnerable to competitive entry or market adoption slowdown. 3) Valuation risk — the forward PE of 34.6x assumes profitability within a year; if this is delayed, the stock could re-rate lower. 4) Technical risk — the stock is in a downtrend with 1-month relative strength of -7.6%, indicating persistent selling pressure. The most severe risk is a growth deceleration below 50% YoY, which could push the stock to its 52-week low of $38.51, a 33% decline from current levels.
The 12-month forecast is based on three scenarios. The base case (50% probability) sees revenue growth moderating to ~70% YoY with continued margin improvement, targeting a price range of $75-$94, in line with the analyst average of $94.56. The bull case (30% probability) assumes the company achieves profitability by Q4 2026 and positive pipeline catalysts, driving the stock to $94-$104 (analyst high target). The bear case (20% probability) involves growth deceleration below 50% YoY and continued losses, pushing the stock to $38-$57 (52-week low of $38.51). The most likely scenario is the base case, given the strong revenue momentum but ongoing profitability challenges. The AI assessment is bullish with medium confidence, citing the 106.9% revenue growth and improving margins as key factors.
TARS appears fairly valued relative to its growth rate but undervalued relative to analyst targets. The trailing PS ratio of 7.58x is in line with the biotechnology industry average of 5-10x for commercial-stage companies, suggesting no excessive premium. The PEG ratio of 1.07x indicates the stock is reasonably priced given expected earnings growth. However, the stock has de-rated significantly from a PS of 23.1x in Q4 2025, reflecting market skepticism about profitability timelines. Compared to its own history, the current PS is near the lower end of the past two years, suggesting a potential value opportunity if the company delivers on earnings expectations. The forward PE of 34.6x implies the market expects a swing to profitability within the next year, which is a critical assumption.
TARS presents a compelling risk/reward for growth-oriented investors. With 106.9% YoY revenue growth, improving margins, and a consensus Strong Buy rating from all 9 analysts, the stock offers significant upside potential — the average target of $94.56 implies 64.4% upside from $57.50. However, the company is still unprofitable (net loss of -$7.0M in Q1 2026) and has negative free cash flow, making it a higher-risk investment. The stock is also in a downtrend, down 28.8% YTD. For investors with a 12-month horizon and high risk tolerance, TARS could be a good buy given the strong fundamentals and analyst support. Conservative investors may prefer to wait for evidence of sustained profitability.
TARS is better suited for medium-term investment (12-24 months) given its growth stage and volatility. The stock has a beta of 0.499, indicating low market correlation, but its 1-month price change of -7.0% and 3-month change of -15.1% show significant company-specific volatility. The company does not pay a dividend, so total return depends on capital appreciation. For long-term investors (3+ years), the risk of single-product concentration and the need for pipeline diversification make it a higher-risk hold. Short-term trading is risky given the downtrend and negative relative strength. A suggested minimum holding period is 12 months to allow for the profitability inflection and potential analyst target realization. Investors should monitor quarterly earnings for signs of sustained growth and margin improvement.